PRLD earnings
Prelude Therapeutics Incorporated (PRLD) earnings releases and earnings dates - real-time wire coverage of every quarterly report.
Recent earnings items
- Prelude Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate UpdateLead candidate from mutant selective JAK2V617F JH2 inhibitor program advancing with IND filing expected in the first quarter of 2026 Lead candidate from oral KAT6A selective degrader program advancing with IND filing expected in mid-2026 Preclinical data from JAK2V617F JH2 inhibitor program and CALR-targeted degrader antibody conjugate (DAC) program were both accepted for oral presentations at the American Society of Hematology (ASH) 67th Annual Meeting in December Current cash runway into 2027 based on preliminary estimates Company to host investor conference call and webcast on Wednesday, November 12, 2025 at 8:00 AM EST WILMINGTON, Del., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Prelude T
- Prelude Therapeutics Announces Strategic Business UpdatePrelude to prioritize development of mutant selective JAK2V617F JH2 inhibitor and KAT6A selective degrader programs Pausing further clinical development of SMARCA2 selective degrader programs JAK2V617F option agreement with Incyte, as previously announced, includes upfront payment of $35 million, a $25 million equity investment and $100 million if option is exercised Cumulative capital expected to fund planned operations into 2027 based on the Company's preliminary estimates, and potentially into the third quarter of 2028 if Incyte exercises option on JAK2 program Company to release third quarter 2025 financial results and conduct an investor conference call on November 12, 2025 WILMIN
- Prelude Therapeutics' SMARCA2 Degrader PRT3789 Demonstrated Promising Initial Clinical Activity and Safety Profile in Phase 1 Trial- Encouraging signs of anti-tumor activity including objective responses observed in patients with SMARCA4-mutated non-small cell lung cancer (NSCLC) and esophageal cancer in early PRT3789 monotherapy dose escalation - At doses studied to date, PRT3789 was generally well-tolerated with no dose-limiting toxicities or study drug-related serious adverse events - Company to host investor conference call and webcast on Friday, September 13, 2024 at 12:00 PM EST WILMINGTON, Del., Sept. 13, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (NASDAQ:PRLD), a clinical-stage precision oncology company, today announced the first interim clinical
- Prelude Therapeutics Announces Publication of Abstract for Presentation at the European Society of Medical Oncology (ESMO) Congress 2024PRT3789, a novel, highly-selective SMARCA2 degrader in patients with advanced solid tumors with a SMARCA4 mutation oral session presentation: September 13, 2024, 4:00 PM CEST (10:00 AM EST) Prelude will host an investor webcast on September 13, 2024, 6:00 PM CEST, (12:00 PM EST) WILMINGTON, Del., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (NASDAQ:PRLD) ("Prelude" or the "Company"), a clinical-stage precision oncology company, today announced the publication of an abstract regarding PRT3789 at the European Society of Medical Oncology (ESMO) Congress 2024 taking place in Barcelona, Spain September 13-17, 2024. The abstract can be found on the ESMO 2024 website
- Prelude Therapeutics Announces Third Quarter 2021 Financial Results and Operations UpdatePRT543 and PRT811 Demonstrate Favorable Safety Profile, Tolerability and Evidence of Preliminary Clinical Activity in Phase 1 Dose Escalation in Unselected Patients Phase 1 Dose Expansion Ongoing in Biomarker-Selected Solid Tumor and Hematologic Malignancy Expansion Cohorts for PRT543; Dose Expansion Portion of Phase 1 Trial of PRT811 to Commence 4Q21 with Data Readouts Anticipated for Both Programs in 2022 PRT2527 IND Cleared by FDA; Phase 1 Clinical Trial Evaluating IV Monotherapy in Patients with Selected Solid Tumors Anticipated to Begin by Year-End Strong Cash, Cash Equivalents and Marketable Securities Position of $320 Million to Support Clinical and Discovery Pipeline Advance
- Prelude Therapeutics Announces Second Quarter 2021 Financial Results and Operations Update- Data from Dose Escalation Portion of Phase 1 Trials of Lead Oral PRMT5 Inhibitors PRT543 and PRT811 to be Presented in 4Q21 – - Enrollment Ongoing in Multiple Expansion Cohorts in Phase 1 Trial of PRT543; Dose Expansion Portion of Phase 1 Trial of PRT811 Expected to Commence in 3Q21 – - Dose Escalation Portion of Phase 1 Trials of Oral and IV Formulations of MCL1 Inhibitor PRT1419 Ongoing – -Strong Cash Position of $343 Million to Support Clinical and Discovery Pipeline Advancement – WILMINGTON, Del., Aug. 12, 2021 (GLOBE NEWSWIRE) -- Prelude Therapeutics Inc. (NASDAQ:PRLD), a clinical-stage precision oncology company, today announced its financial results for the s
- Prelude Therapeutics Announces First Quarter 2021 Financial Results and Operations Update- Enrollment Now Underway in Multiple Solid Tumor and Hematologic Malignancy Expansion Cohorts in Phase 1 Trial of Oral PRMT5 Inhibitor PRT543 - - Initial Clinical Data Readouts for Lead Oral PRMT5 Inhibitors PRT543 and PRT811 Expected in 2H21 - - Dose Escalation Ongoing in Phase 1 Trial of Oral MCL1 Inhibitor PRT1419, with Dose Expansion Cohorts on Track to be Added in 2H21 - WILMINGTON, Del., May 11, 2021 (GLOBE NEWSWIRE) -- Prelude Therapeutics Inc. (NASDAQ:PRLD), a clinical-stage precision oncology company, today announced its financial results for the first quarter ended March 31, 2021 and provided an update on recent clinical and development pipeline progress. "With sever